StockTipsArenaBeta

BUY Mankind Pharma Limited — Rajesh Satpute

BUYMankind Pharma Limited
Mankind Pharma share price target & all analyst calls

byRajesh SatputeHorizon: NA (inferred Intraday)19 Aug 2026, 11:51 am ISTvia CNBC Awaaz.

Entry₹2,392.1Inferred
Target₹2,450
Total upside +2.42% (call closed)
Stop loss₹2,380-0.51% risk
At expiry₹2,390.919 Aug 2026, 3:05 pm
Expired-0.05%
Follow Rajesh Satpute for new calls(8% target hit, 124 closed calls)Get alertsWatch MANKIND for new buy/sell callsGet alerts

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 19 Aug 2026
3 supporting2 neutral0 opposing
Supports the BUY call (3)

Mankind Pharma Q1 Revenue Up 13% to ₹4,030 Crore; Stock Gains 2%

NewsGoogle News·14 Aug · 5d ago

(opens in new tab)

Mankind Pharma Share Price: दमदार नतीजे! रेवेन्यू **13%** बढ़ा, शेयर में **2%** की उछाल

NewsGoogle News·14 Aug · 5d ago

(opens in new tab)

Mankind Pharma शेअर तेजीत! तिमाहीत ₹4,030 कोटी महसूल, नफ्यात तब्बल **29%** वाढ

NewsGoogle News·14 Aug · 5d ago

(opens in new tab)
Neutral / worth noting (2)

Mankind Pharma completes security realignment and releases pledged shares worth 38.68% of Bharat Serums and Vaccines' equity

NewsGoogle News·17 Aug · yesterday

(opens in new tab)

Mankind Pharma Releases BSVL Share Pledge, Realignment of NCD Security Complete

NewsGoogle News·17 Aug · yesterday

(opens in new tab)
Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Mankind Pharma

All analyst calls on Mankind Pharma

More from Rajesh Satpute

Every call and its outcome